Skip to content

Advertisement

  • Poster presentation
  • Open Access

Efficacy of a second TNF blocker, when the first one failed, in patients with juvenile idiopathic arthritis (JIA)

  • 1,
  • 2,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Pediatric Rheumatology20086 (Suppl 1) :P44

https://doi.org/10.1186/1546-0096-6-S1-P44

  • Published:

Keywords

  • Arthritis
  • Infliximab
  • Etanercept
  • Juvenile Idiopathic Arthritis
  • Psoriatic Arthritis

Objectives

To determine the efficacy of a second treatment with a different TNF blocker in JIA when the first one failed.

Methods

All JIA patients prospectively followed at our Centre, who failed a first TNF blocker and switched to a second one were enrolled. For each patient the DAS, ACR Ped30, ACR20, ACR50 and ACR70 responses were evaluated at baseline and after a period ranging from 3 to 6 months of each treatment.

Results

Out of 60 JIA patients enrolled, 40 (37 f, 3 m) were evaluated: 10 systemic arthritis, 2 persistent oligoarthritis, 11 extended oligoarthritis, 9 RF negative polyarthritis, 4 RF positive polyarthritis, 1 ERA (enthesitis related arthritis), 3 psoriatic arthritis. With a standard Chi square model, we didn't find a significant difference in the ACR and DAS response rates between the first and the second anti TNF treatment (p > 0.1). Stratifying the population for the type of the shift (Etanercept to Infliximab/Adalimumab, Infliximab to Etanercept/Adalimumab) we didn't find a significant difference in the ACR and DAS response rates between the first and the second anti TNF treatment (p > 0.1). Our data show that failure of an anti-TNF therapy in patients with JIA does not preclude a response to a second anti-TNF agent of a different class.

Authors’ Affiliations

(1)
Gaetano Pini Institute Chair of Rheumatology, Milan, Italy
(2)
Fornaroli Hospital Rheumatology Unit, Magenta, Italy

Copyright

© Salmaso et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement